Intelligent Bio Solutions Inc. (INBS)
| Market Cap | 4.63M -50.5% |
| Revenue (ttm) | 4.22M +38.1% |
| Net Income | -12.43M |
| EPS | -8.44 |
| Shares Out | 3.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,790 |
| Open | 1.460 |
| Previous Close | 1.500 |
| Day's Range | 1.450 - 1.550 |
| 52-Week Range | 1.350 - 24.900 |
| Beta | 4.30 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 11, 2026 |
About INBS
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporate... [Read more]
Financial Performance
In fiscal year 2026, Intelligent Bio Solutions's revenue was $4.22 million, an increase of 38.09% compared to the previous year's $3.05 million. Losses were -$12.43 million, 17.6% more than in 2025.
Financial StatementsNews
Intelligent Bio Solutions Slides: Investor presentation
Intelligent Bio Solutions has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Intelligent Bio Solutions Transcript: Fireside chat
The discussion highlighted the company's rapid revenue growth, innovative drug screening technology, and robust FDA submission process. Plans include U.S. market entry, expanding the drug panel, and faster testing for new applications like roadside law enforcement.
Intelligent Bio Solutions Registration statement: Registration filing
Intelligent Bio Solutions filed a registration statement on September 15, 2026, providing details about a securities offering with the SEC.
Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET
Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S. Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S...
Intelligent Bio Solutions submits 510 premarket notification to FDA
Intelligent Bio Solutions (INBS) announced the submission of its 510 premarket notification to the FDA, seeking regulatory clearance of its Intelligent Fingerprinting Drug Screening System for detecti...
Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing s...
Intelligent Bio Solutions announces private placement of up to $15M
Intelligent Bio Solutions (INBS) announced that it has entered into a securities purchase agreement with a single existing institutional investor to issue, in a private placement priced at-the-market ...
Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission
Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System Multi-site clinical study delivers strong performance data for Intelligent Fingerprintin...
Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules
$5 Million Upfront at Closing and $5 Million Tranche Warrant Callable by the Company Following FDA 510(k) Clearance of Intelligent Fingerprinting Drug Screening System $5 Million Upfront at Closing an...
Intelligent Bio Solutions Slides: Investor presentation
Intelligent Bio Solutions has posted slides in relation to its latest quarterly earnings report, which was published on August 28, 2026.
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth
Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units
Intelligent Bio Solutions Annual report: Q4 2026
Intelligent Bio Solutions has published its Q4 2026 annual report on August 19, 2026.
Intelligent Bio Solutions Earnings release: Q4 2026
Intelligent Bio Solutions released its Q4 2026 earnings on August 19, 2026, summarizing the period's financial results.
Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification
Recertification aligns with the FDA's newly amended Quality Management System Regulation and supports the Company's regulatory strategy as it pursues FDA clearance Recertification aligns with the FDA'...
Intelligent Bio Solutions completes fingerprint drug screening study
Intelligent Bio Solutions (INBS) announced the completion of its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System, one of several studies underpinning the co...
Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so...
Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so...
Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System
NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so...
Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry
Company has addressed final review items from penetration testing and finalized cybersecurity and software documentation
Intelligent Bio Solutions completes precision testing for drug screening system
Intelligent Bio Solutions (INBS) announced the completion of precision testing, a key component of the company’s FDA 510 submission for U.S. market clearance of its Intelligent Fingerprinting Drug Scr...
Intelligent Bio Solutions Slides: Corporate presentation
Intelligent Bio Solutions has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2026.
Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market
Precision testing confirms reproducibility across more than 1,600 tests, three production runs, and three independent testing sites Precision testing confirms reproducibility across more than 1,600 te...
Intelligent Bio Solutions Transcript: Planet MicroCap Las Vegas 2026
A non-invasive drug testing device using fingertip sweat delivers results in 10 minutes and features the industry's shortest detection window, targeting workplace impairment. The business is expanding globally, shifting manufacturing to Asia for higher margins, and is preparing for FDA submission in the U.S.
Intelligent Bio Solutions Slides: Investor presentation
Intelligent Bio Solutions has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry
Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings